Results 71 to 80 of about 50,051 (221)

Fighting viral infections and virus-driven tumors with cytotoxic CD4+ T cells [PDF]

open access: yes, 2017
CD4+ T cells have been and are still largely regarded as the orchestrators of immune responses, being able to differentiate into distinct T helper cell populations based on differentiation signals, transcription factor expression, cytokine secretion, and
Adhikary   +229 more
core   +2 more sources

A Modular Vaccine Platform Against SARS‐CoV‐2 Based on Self‐Assembled Protein Nanoparticles

open access: yesAdvanced Science, EarlyView.
A modular BP26 nanoparticle vaccine platform incorporating the SpyTag/SpyCatcher system enables high‐density, repetitive antigen display with post‐expression flexibility. Conjugation of the SARS‐CoV‐2 RBD to BP26 nanoparticles elicits strong humoral immunity and confers protection against viral challenge in vivo.
Seojung Lee   +6 more
wiley   +1 more source

Annual Universal Influenza Vaccination: Ready or Not? [PDF]

open access: yesClinical Infectious Diseases, 2006
Influenza causes annual worldwide epidemics of respiratory disease. Currently, the United States and many other countries recommend influenza vaccination for persons who are at high risk for influenza-related complications. This commentary explores the potential benefits of a policy advocating universal annual influenza vaccination and outlines ...
Bruce Gellin   +4 more
openaire   +2 more sources

DNA Nanostructure‐Templated Multivalency Enables Broad‐Spectrum Virus Inhibition

open access: yesAdvanced Science, EarlyView.
A honeycomb‐shaped DNA nanostructure is introduced that organizes nanobodies or aptamers into trimeric clusters mirroring the native hemagglutinin arrangement on influenza viruses. This geometry‐matched multivalency enhances binding avidity by up to 1000‐fold, resulting in robust, broad‐spectrum viral neutralization and a 30–55% improvement in host ...
Saurabh Umrao   +8 more
wiley   +1 more source

Efforts to Improve the Seasonal Influenza Vaccine

open access: yesVaccines, 2018
Influenza viruses infect approximately 20% of the global population annually, resulting in hundreds of thousands of deaths. While there are Food and Drug Administration (FDA) approved antiviral drugs for combating the disease, vaccination remains the ...
Alfred T. Harding, Nicholas S. Heaton
doaj   +1 more source

Unconjugated Multi-Epitope Peptides Adjuvanted with ALFQ Induce Durable and Broadly Reactive Antibodies to Human and Avian Influenza Viruses

open access: yesVaccines, 2023
An unconjugated composite peptide vaccine targeting multiple conserved influenza epitopes from hemagglutinin, neuraminidase, and matrix protein and formulated with a safe and highly potent adjuvant, Army Liposome formulation (ALFQ), generated broad and ...
Nimisha Rikhi   +12 more
doaj   +1 more source

TIV vaccination modulates host responses to influenza virus infection that correlate with protection against bacterial superinfection [PDF]

open access: yes, 2019
Background: Influenza virus infection predisposes to secondary bacterial pneumonia. Currently licensed influenza vaccines aim at the induction of neutralizing antibodies and are less effective if the induction of neutralizing antibodies is low and/or the
Choi, Angela   +4 more
core   +2 more sources

Antiemesis Corticosteroids Potentiate Checkpoint Blockade Efficacy by Normalizing the Immune Microenvironment in Metastatic Murine Breast Cancer

open access: yesAdvanced Science, EarlyView.
Corticosteroids improve the efficacy of immune checkpoint blockade therapy in metastatic murine breast cancer. By normalizing the tumor immune microenvironment, corticosteroids reduce immunosuppressive signals, restore T‐cell function, and promote antitumor immune responses, resulting in enhanced tumor control.
John D. Martin   +19 more
wiley   +1 more source

Multivalent Epigraph Hemagglutinin Vaccine Protects against Influenza B Virus in Mice

open access: yesPathogens
Influenza B virus is a respiratory pathogen that contributes to seasonal epidemics, accounts for approximately 25% of global influenza infections, and can induce severe disease in young children.
Erika Petro-Turnquist   +4 more
doaj   +1 more source

Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection. [PDF]

open access: yesPLoS ONE, 2013
Influenza vaccines that target the highly variable surface glycoproteins hemagglutinin and neuraminidase cause inconvenience of having vaccination every year.
So-Hee Kim   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy